Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.32 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.31 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5494802 | 0.86 | ITGA4 (0.36) | GSK3BDYRK1AITGA4ITGB7MAPKAPK2 | |
| SCHEMBL5494797 | 0.86 | ITGA4 (0.36) | GSK3BDYRK1AITGA4ITGB7MAPKAPK2 | |
| SCHEMBL5493523 | 0.85 | MAPKAPK2 (0.32) | MAPKAPK2NR1H4 | |
| SCHEMBL3123164 | 0.79 | SIRT5 (0.37) | ITGA4ITGB7 | |
| SCHEMBL3227631 | 0.79 | SIRT5 (0.37) | ITGA4ITGB7 | |
| SCHEMBL3227645 | 0.79 | SIRT5 (0.37) | ITGA4ITGB7 | |
| SCHEMBL3123178 | 0.79 | SIRT5 (0.37) | ITGA4ITGB7 | |
| SCHEMBL3117506 | 0.79 | SIRT5 (0.40) | — | |
| SCHEMBL3117516 | 0.79 | SIRT5 (0.40) | — | |
| SCHEMBL5498909 | 0.78 | LPAR1 (0.35) | GSK3BDYRK1AITGA4ITGB7RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556389-B9 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2015-09-09 | — | — | EP | disclosed |
| EP-1556389-B3 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2015-04-01 | — | — | EP | disclosed |
| EP-1556389-B1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2007-07-25 | — | — | EP | disclosed |
| US-20070037786-A1 | Cephem compounds | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| US-7129232-B2 | For therapy of of infectious diseases | ASTELLAS PHARMA INC. (JP) | 2006-10-31 | — | — | US | disclosed |
| US-20040132994-A1 | Cephem compounds | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037786-A1 | Cephem compounds | CEP170, ABCB11, SLC7A1 | GSK3B 3672/4885DYRK1A 3303/4885ITGA4 3736/4885 |
| US-20040132994-A1 | Cephem compounds | CEP170, ABCB11, RCC2 | GSK3B 3845/4885DYRK1A 4036/4885ITGA4 3512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.